Market Place
Sourcing Support
HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
16 Oct 2024 //
GLOBENEWSWIRE
HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
08 Sep 2024 //
GLOBENEWSWIRE
China NMPA accepts for review Hutchmed’s sNDA for savolitinib
29 Mar 2024 //
PHARMABIZ
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC
27 Mar 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib
12 Sep 2023 //
GLOBENEWSWIRE
HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
29 Aug 2023 //
PRESS RELEASE
HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
28 Aug 2023 //
GLOBENEWSWIRE
Hutchmed Initiates Registration Phase Enrollments of HMPL-453
04 Apr 2023 //
GLOBENEWSWIRE
Quotient Sciences Contributes to Clinical Pharmacology in Drug Development article, "A Phase 1 Study of Savolitinib"
19 Feb 2023 //
PRESS RELEASE
Tagrisso combined with Hutchmed drug clears lung cancer test
10 Aug 2022 //
PHARMA FILE
HUTCHMED, AstraZeneca`s TAGRISSO Plus Savolitinib Demonstrated 49% ORR
08 Aug 2022 //
GLOBENEWSWIRE
HUTCHMED Shows 1st Presentation of Results of SAVANNAH PII Trial of Savolitinib
12 Jul 2022 //
GLOBENEWSWIRE
Hutchmed, AZ begin phase III trial of Orpathys, Tagrisso combo in lung cancer
26 Nov 2021 //
PHARMABIZ
HUTCHMED & AZ Initiate SAMETA Global Phase III Trial of Savolitinib
30 Oct 2021 //
GLOBENEWSWIRE
HUTCHMED and AstraZeneca Initiate SANOVO PIII Trial of ORPATHYS and TAGRISSO
08 Sep 2021 //
GLOBENEWSWIRE
Could the anti-cancer gene p53 be a target in treating kidney cancer?
21 Dec 2019 //
FIERCE BIOTECH
Chi-Med highlights publication of Phase II data for Savolitinib
18 Oct 2019 //
BIOSPACE
Chi-Med cuts surufatinib PhIII short
17 Jun 2019 //
ENDPTS
Savolitinib found to treatment-resistant lung cancer in combo with AZ’s Tagrisso
03 Apr 2019 //
PHARMA TIMES
Chi-Med`s savolitinib helps Tagrisso-resistant patients
01 Apr 2019 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.